Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation...

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Chronic lymphocytic leukemia (CLL) exhibits distinct subtypes based on immunoglobulin gene mutation status (M-CLL vs. U-CLL).
• These subtypes differ in anergy, genetic aberrations, and DNA methylation, reflecting their maturational status and clinical course.

Purpose of the Study:

• To investigate the role of surface immunoglobulin M (sIgM) expression and signaling in CLL.
• To explore correlations between sIgM levels, genetic features, DNA methylation, and clinical outcome.

Main Methods:

• Quantification of sIgM levels and intracellular calcium (Ca2+) mobilization upon stimulation.
• Analysis of genetic aberrations (+12, del(17p), NOTCH1 mutations).
• DNA methylation profiling using an 18-gene panel to assess maturation status.

Main Results:

• U-CLL generally displayed higher sIgM levels and signaling than M-CLL.
• Increased sIgM levels/signaling correlated with disease progression within both CLL subtypes.
• In U-CLL, high sIgM associated with specific genetic lesions; in M-CLL, lower sIgM correlated with higher methylation maturation status.
• Multivariate analysis identified high sIgM as a potential independent predictor of CLL progression.

Conclusions:

• sIgM levels are influenced by cell origin, antigen exposure, and genetic damage.
• High sIgM is a novel potential prognostic factor for CLL, particularly valuable in the heterogeneous M-CLL subset.
• Further investigation of sIgM as a predictive marker for clinical behavior is warranted.